Replay available

Standard BioTools Inc. (LAB) Q3 2024 Earnings Call

Standard BioTools Inc. (NASDAQ: LAB) Q3 2024 earnings conference call, held 2024-10-30. Replay captured from the company's public earnings webcast.

Wed, October 30, 2024 at 4:30 PMendedReplay
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

David Holmes

Head of Investor Relations

Michael Eggholm

President and Chief Executive Officer

Alex Kim

Chief Operating Officer and Interim Chief Financial Officer

Matt Stanton

Analyst, Jefferies

Replay transcript excerpt

Good day, and welcome to the Standard BioTools, Inc. Third Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to David Holmes of Investor Relations. Please go ahead. Thank you, Operator, and good afternoon, everyone. Welcome to Standard BioTools' third quarter 2024 earnings conference call. Leading the call today is Michael Eggholm, President and Chief Executive Officer, and Alex Kim, Chief Operating Officer and Interim Chief Financial Officer. At the close of Market Today, Standard BioTools released its financial results for the quarter ended September 30th, 2024. During this call, we will review our results and provide an update of our financial and operational performance, 2024 outlook, market trends, and strategic initiatives. During the call, we will make forward-looking statements about events and circumstances that have not yet occurred. including plans and projections for our business, our outlook for 2024 and future financial results, market trends and opportunities, and our expectations related to the combined operations with Somalogic, including potential synergies and our business outlook for the combined company. These statements are subject to substantial risks and uncertainties that may cause actual events or results to differ materially from current circumstances. The forward-looking statements on this call are bas...

More from Standard Biotools Inc.